A Bad Year for Pharmaceutical R&D - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Bad Year for Pharmaceutical R&D


ePT--the Electronic Newsletter of Pharmaceutical Technology

Figures released by the European Medicines Agency (EMA) regarding the evaluation of marketing-authorization (MA) applications show a significant decline in the number of approved products for 2010. Only 38 positive opinions were issued as of October 2010, compared with 117 in 2009. The number of negative opinions is also low, with just two issued so far this year compared with eight in 2009.

All in all, the number of started and finalized MA applications has declined significantly, reflecting drying industry pipelines. In 2009, EMA started and finalized 95 and 125 MA applications, respectively, compared with only 75 and 41 in 2010. The 2010 figures span the period from January through October 2010. The figures may yet increase, but it seems unlikely that they will match those of 2009.

Despite views that pharmaceutical innovation and productivity have been lagging for some time, the figures show that MA applications to EMA have actually been increasing, or at least remaining relatively stable, over the past few years. In 2007, EMA started and finalized 90 and 65 MA applications, respectively, and these numbers increased in 2008 to 103 and 72 applications. In 2009, there was a slight decline in started MA applications (down to 84), but a major increase in finalized applications (114). Also in 2009, there was a huge increase in the number of generic MA applications (38 started and 51 finalized).

For 2010, the decline in MA applications encompasses both new products and generics and is particularly marked in finalized applications. Only 18 applications were finalized for new products (down from 49 in 2009) while generics applications dropped to 15.

The EMA has said that it will provide monthly updates on its website concerning the volume and evaluation of MA and post-authorization applications. The full picture for 2010 will not be clear until early next year, however. EMA also said that it will provide commentaries and analyses of the figures in its own annual report.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here